Astrocytes in Amyotrophic Lateral Sclerosis <table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Astrocytes in ALS</th>
</tr>
<tr>
<td class="label">
Category </td>
<td>Glial Cells</td>
</tr>
<tr>
<td class="label">
Location </td>
<td>Motor cortex, spinal cord anterior horn, brainstem</td>
</tr>
<tr>
<td class="label">
Cell Type </td>
<td>Reactive astrocytes (A1/A2 phenotype)</td>
</tr>
<tr>
<td class="label">
Markers </td>
<td>GFAP, AQP4, S100B, ALDH1L1</td>
</tr>
<tr>
<td class="label">
Disease </td>
<td>Amyotrophic Lateral Sclerosis</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Change</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>↑ 3-5x</td>
</tr>
<tr>
<td class="label">C3</td>
<td>↑ 10-50x</td>
</tr>
<tr>
<td class="label">S100B</td>
<td>↑</td>
</tr>
<tr>
<td class="label">EAAT2</td>
<td>↓ 50-80%</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">
Riluzole </td>
<td>Approved</td>
</tr>
<tr>
<td class="label">
Edaravone </td>
<td>Approved</td>
</tr>
<tr>
<td class="label">
Celecoxib </td>
<td>Trial</td>
</tr>
<tr>
<td class="label">
CNTF delivery </td>
<td>Trial</td>
</tr>
<tr>
<td class="label">
GDNF delivery </td>
<td>Trial</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Features</td>
</tr>
<tr>
<td class="label">
SOD1G93A mice </td>
<td>Standard ALS mo
...
Astrocytes in Amyotrophic Lateral Sclerosis <table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Astrocytes in ALS</th>
</tr>
<tr>
<td class="label">
Category </td>
<td>Glial Cells</td>
</tr>
<tr>
<td class="label">
Location </td>
<td>Motor cortex, spinal cord anterior horn, brainstem</td>
</tr>
<tr>
<td class="label">
Cell Type </td>
<td>Reactive astrocytes (A1/A2 phenotype)</td>
</tr>
<tr>
<td class="label">
Markers </td>
<td>GFAP, AQP4, S100B, ALDH1L1</td>
</tr>
<tr>
<td class="label">
Disease </td>
<td>Amyotrophic Lateral Sclerosis</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Change</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>↑ 3-5x</td>
</tr>
<tr>
<td class="label">C3</td>
<td>↑ 10-50x</td>
</tr>
<tr>
<td class="label">S100B</td>
<td>↑</td>
</tr>
<tr>
<td class="label">EAAT2</td>
<td>↓ 50-80%</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">
Riluzole </td>
<td>Approved</td>
</tr>
<tr>
<td class="label">
Edaravone </td>
<td>Approved</td>
</tr>
<tr>
<td class="label">
Celecoxib </td>
<td>Trial</td>
</tr>
<tr>
<td class="label">
CNTF delivery </td>
<td>Trial</td>
</tr>
<tr>
<td class="label">
GDNF delivery </td>
<td>Trial</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Features</td>
</tr>
<tr>
<td class="label">
SOD1G93A mice </td>
<td>Standard ALS model, rapid progression</td>
</tr>
<tr>
<td class="label">
SOD1G37R mice </td>
<td>Slower progression, later onset</td>
</tr>
<tr>
<td class="label">
C9orf72 mice </td>
<td>Models hexanucleotide expansion</td>
</tr>
<tr>
<td class="label">
Astrocyte-specific SOD1 </td>
<td>Demonstrates non-cell autonomy</td>
</tr>
<tr>
<td class="label">
iPSC-derived astrocytes </td>
<td>Patient-specific research</td>
</tr>
</table>
Introduction Astrocytes In Als is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Overview
Normal Astrocyte Functions
Homeostatic Support
Potassium buffering : Kir4.1 channel-mediated K+ uptake maintains extracellular K+ homeostasisWater balance : AQP4 channels regulate water flux at the blood-brain barrierpH regulation : Carbonic anhydrase activity maintains acid-base balanceLactate shuttle : Provides metabolic substrates to neuronsGlycogen storage : Energy reserve for neural activityTricarboxylic acid cycle : Supports oxidative phosphorylation in neuronsNeurotransmitter Regulation
Glutamate uptake : EAAT1 (GLAST) and EAAT2 (GLT-1) transporters clear extracellular glutamateGABA recycling : GABA transaminase metabolismAmmonia detoxification : Glutamine synthesisSynaptic Function
Synapse formation : Promote excitatory and inhibitory synapse formationPerisynaptic astrocytic processes : Modulate synaptic transmissionTripartite synapse : Integral component of synaptic architectureAstrocyte Dysfunction in ALS
Reactive Astrocyte Phenotype
A1 Neurotoxic Phenotype ALS astrocytes acquire an A1-like reactive phenotype similar to that observed in Alzheimer's disease and Parkinson's disease: [@di2008]
Upregulated genes : GFAP, S100B, C3, Serpina3n, complement componentsDownregulated genes : Glutamate transporters, Kir4.1, AQP4Function : Gain of toxic functions, loss of supportive functionsPhenotypic Markers
Mechanisms of Motor Neuron Toxicity
1. Glutamate Excitotoxicity
EAAT2/GLT-1 downregulation : 50-80% reduction in ALS spinal cordReduced glutamate clearance : Extracellular glutamate accumulatesAMPA/Kainate receptor overactivation : Ca²⁺ influx, excitotoxic deathTherapeutic target : Riluzole (glutamate modulator)2. Mitochondrial Dysfunction
Reduced oxidative phosphorylation : ATP depletionIncreased ROS production : Oxidative stressImpaired calcium handling : Vulnerability to excitotoxicityMutant SOD1 effects : Direct mitochondrial damage3. Neuroinflammation
Pro-inflammatory cytokines : IL-1β, IL-6, TNF-αChemokine secretion : CCL2, CXCL10 recruitment of immune cellsComplement activation : C1q, C3-mediated synapse eliminationNF-κB activation : Persistent inflammatory stateLactate production defects : Energy starvation of motor neuronsImpaired glycogenolysis : Loss of energy reservesReduced pyruvate carrier : Altered glucose metabolism5. Loss of Trophic Support
Reduced BDNF secretion : Survival factor deficiencyImpaired GDNF signaling : Motor neuron protection lossDefective Notch signaling : Developmental dysregulation
SOD1 Mutations
Over 150 mutations : A4V, G93A, G37R, etc.Astrocyte-specific effects : Mutant SOD1 expressed in astrocytesNon-cell autonomous toxicity : Astrocyte-to-motor neuron spreadC9orf72 Expansion
Hexanucleotide repeat expansion : Most common genetic causeDipeptide repeat proteins (DPRs) : Toxic to astrocytesRNA foci formation : Sequestration of RNA-binding proteinsTDP-43 Pathology
Cytoplasmic inclusions : Found in 97% of ALS casesAstrocyte involvement : TDP-43 aggregates in astrocytesRNA splicing defects : Global dysregulationFUS Mutations
Fused in Sarcoma (FUS) : RNA-binding protein mutationsAstrocyte nuclear loss : Cytoplasmic mislocalizationImpaired RNA metabolism : Widespread splicing defectsTherapeutic Implications
Astrocyte-Targeted Therapies
Emerging Strategies
Astrocyte reprogramming : Converting to protective phenotypeiPSC-derived astrocytes : Patient-specific disease modelingGene therapy : Targeting astrocyte-specific pathwaysMicroRNA therapy : Modulating astrocyte functionAnimal Models
Cross-Links
Amyotrophic Lateral Sclerosis - Main disease page
Motor Neurons - Motor neuron biology
GFAP (Glial Fibrillary Acidic Protein) - Astrocyte marker
[Neuroinflammation](/mechanisms/neuroinflamm- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)s
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) Energy failure
Excitotoxicity - Glutamate toxicity
SOD1 Gene - Superoxide dismutase
Background The study of Astrocytes In Als has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
[Tau Pathology](/mechanisms/tau-pathology)
[Parkinson's Disease](/diseases/parkinsons-disease)
[α-Synuclein](/proteins/alpha-synuclein)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
External Links
[ALS - NIH](https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als)
[Astrocytes in Disease - Scholar](https://en.wikipedia.org/wiki/Astrocyte)
Show full description